Why Aurora Cannabis Inc (ACB) Stock Is Rising
As of 2026-08-25, Aurora Cannabis Inc (ACB) has a next-year EPS growth estimate of 161.79%. Featured in 4 EPS revision reports, most recently on 2026-08-17.
Why ACB Stock Is Rising
- +EPS Estimate Upgraded: Analysts raised Aurora Cannabis Inc's next-year EPS growth estimate from 161.75% to 161.79% on 2026-08-19.
- ·Current-Year Growth: Projected at 86.25%, supporting the forward estimate revision.
News Context
Analysts nudged Aurora Cannabis’s next-year EPS growth estimate up slightly from 161.75% to 161.79%, serving as a structural driver behind the stock’s rise. The move is plausibly tied to Aurora’s fiscal Q4 2026 results, which featured record annual revenue and adjusted EBITDA, alongside its accretive acquisition of Internode and HAP Pharma to expand UK medical cannabis distribution. The upward trend has continued past the initial revision, supported by follow-on headlines such as EU-GMP certification for its Niagara facility.
Generated 2026-08-25 · news as of 2026-08-25
Current Snapshot
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- EPS growth next year
- 161.79%
- EPS growth this year
- 86.25%
- EPS next quarter (est)
- -$0.05
- Last price
- $4.01
EPS Revision History
| Date | EPS Next Y | EPS This Y | Next Q (est) | Price |
|---|---|---|---|---|
| 2026-08-25 | 161.79% | 86.25% | -$0.05 | $4.01 |
| 2026-08-24 | 161.79% | 86.25% | -$0.05 | $3.94 |
| 2026-08-23 | 161.79% | 86.25% | -$0.05 | $3.94 |
| 2026-08-21 | 161.79% | 86.25% | -$0.05 | $3.94 |
| 2026-08-20 | 161.79% | 86.25% | -$0.05 | $3.81 |
| 2026-08-19 | 161.79% | 86.25% | -$0.05 | $3.91 |
| 2026-08-18 | 161.75% | 86.21% | -$0.05 | $3.67 |
| 2026-08-17 | 161.75% | 86.21% | -$0.05 | $3.60 |
| 2026-08-16 | 161.75% | 86.21% | -$0.05 | $3.68 |
| 2026-08-14 | 161.75% | 86.21% | -$0.05 | $3.68 |
| 2026-08-13 | 161.75% | 86.21% | -$0.05 | $3.79 |
| 2026-08-12 | 161.75% | 86.21% | -$0.05 | $3.82 |
| 2026-08-11 | 161.75% | 86.21% | -$0.05 | $3.48 |
| 2026-08-10 | 161.75% | 86.21% | -$0.05 | $2.89 |
| 2026-08-09 | 161.75% | 86.21% | -$0.05 | $2.99 |
| 2026-08-07 | 161.30% | 86.20% | -$0.05 | $2.99 |
| 2026-08-06 | 107.53% | 81.16% | -$0.06 | $2.98 |
| 2026-08-05 | 91.45% | 66.55% | -$0.13 | $2.91 |
| 2026-08-04 | 91.45% | 66.46% | -$0.13 | $2.81 |
| 2026-08-03 | 91.45% | 66.46% | -$0.13 | $2.83 |
| 2026-08-02 | 91.45% | 66.46% | -$0.13 | $2.79 |
| 2026-07-31 | 91.45% | 66.46% | -$0.13 | $2.79 |
| 2026-07-30 | 91.45% | 66.46% | -$0.13 | $2.83 |
| 2026-07-29 | 91.45% | 66.46% | -$0.13 | $2.73 |
| 2026-07-28 | 91.45% | 66.46% | -$0.13 | $2.72 |
| 2026-07-27 | 91.45% | 66.46% | -$0.13 | $2.74 |
| 2026-07-26 | 90.92% | 68.55% | -$0.13 | $2.67 |
| 2026-07-24 | 90.92% | 68.55% | -$0.13 | $2.67 |
| 2026-07-23 | 90.92% | 68.55% | -$0.13 | $2.69 |
| 2026-07-22 | 90.90% | 68.53% | -$0.13 | $2.66 |
Reports Featuring ACB
- 2026-08-17
SNDK Soars 45.9% After EPS Revision, AI Memory Boom Fuels Rally
- 2026-08-14
SHAZ Soars 53.6% on AI Capacity Surge; SNDK, ACB Rally on EPS Revisions
- 2026-08-13
SHAZ Surges 44.6% on AI Capacity Expansion; SNDK, ACB, CLMT, NYXH Follow
- 2026-08-12
SHAZ Soars 37.5% as AI Capacity Surges; Top EPS Revision Gainers
Recent News
- Aurora Cannabis Furthers Global Medical Cannabis Growth with Accretive Acquisition of Internode Pharma Limited and HAP Pharma Limited, Expanding Distribution Access to the UK Medical Cannabis MarketPR Newswire
- AURORA CANNABIS INC. URGES SHAREHOLDERS TO TAKE NO ACTION AT THIS TIME IN RESPECT TO THE UNSOLICITED TAKE-OVER BID BY CURALEAF HOLDINGS, INC.PR Newswire
- Curaleaf CEO talks unsolicited offer to buy Aurora CannabisCNBC TV
- Why Aurora Cannabis Looks Cheaper Than Its International Growth Suggests Quarterly Update ReportExec Edge
- Why Aurora Cannabis Looks Cheaper Than Its International Growth Suggests Downloadable Quarterly Update ReportExec Edge
- Safari Flower Company, a Wholly Owned Subsidiary of Aurora Cannabis, Receives EU-GMP Certification at Niagara FacilityPR Newswire
- Aurora Cannabis Inc (ACB) Q4 2026 Earnings Call Highlights: Strong Revenue Growth Amid ...GuruFocus.com
- Aurora Cannabis Announces Full Year and Fiscal 2026 Fourth Quarter Results with Record Annual Revenue and Adjusted EBITDA¹PR Newswire
Screen Performance
Aggregate stats across all 2014 tickers our top-EPS-revision screen has flagged over the past 146 days.
- Median return since detection
- +3.1%
- % of tickers in the green
- 56%
- Median return on winners
- +19.9%
- Large revisions captured
- 1606
Past detection performance reflects the price change between when a ticker first entered our screen and the most recent observation. Not a forward-looking forecast.
Also Tracked by Our Screen
Frequently Asked Questions
Why did Aurora Cannabis Inc (ACB) stock go up recently?▾
Aurora Cannabis Inc (ACB) stock has risen following an analyst upgrade of its next-year EPS growth estimate from 161.75% to 161.79% on 2026-08-19. EPS estimate upgrades are among the strongest leading indicators of stock outperformance.
What is Aurora Cannabis Inc's next-year EPS growth estimate?▾
As of 2026-08-25, Aurora Cannabis Inc (ACB) has a next-year EPS growth estimate of 161.79%, based on analyst consensus.
When was the latest EPS estimate revision for ACB?▾
The most recent revision occurred on 2026-08-19, when analysts adjusted the next-year EPS growth estimate from 161.75% to 161.79%.
What sector and industry does Aurora Cannabis Inc belong to?▾
Aurora Cannabis Inc operates in the Healthcare sector, specifically the Drug Manufacturers - Specialty & Generic industry.
How often is this EPS estimate data updated?▾
EPS revision data is refreshed daily from analyst consensus estimates. ACB appears on this page because it was flagged by our daily top-EPS-revision-performer screen.
EPS revision data sourced from analyst consensus estimates, refreshed daily. Aurora Cannabis Inc (ACB) appears here because it was detected by our daily top-EPS-revision-performer screen.